To apply a multidisciplinary approach to the identification and pharmacological characterization of the serotonin (5HT) receptors that mediate functional responses in human trabecular meshwork (h-TM) cells. To correlate in vitro findings with intraocular pressure (IOP) G laucoma is the second major cause of irreversible legal blindness in the human population in the world.
G laucoma is the second major cause of irreversible legal blindness in the human population in the world. 1 It is estimated that 3.3 million people in the United States will have glaucoma by 2020. 1 Because the major risk factor for glaucoma is elevated intraocular pressure (IOP), various pharmaceutical agents have been discovered for treating ocular hypertension, including FP-class prostaglandin analogues, 2,3 ␤-blockers, ␣-2 adrenergic agonists, carbonic anhydrase inhibitors and muscarinic agonists (for reviews, see Refs. 4, 5) . However, despite the availability of such therapeutic agents, many patients with glaucoma remain either refractory toward several of these drugs or exhibit significant side-effects, such that there continues to be a critical need for novel ocular hypotensive drugs.
Serotonin (5-hydroxy tryptamine; 5HT), is a major endogenous amine neurotransmitter in the mammalian central nervous system 6 that has also been detected in the aqueous humor 7, 8 and iris-ciliary body 9 of human subjects. Furthermore, serotonergic nerves have been shown to innervate various ocular tissues including the iris-ciliary body. 10 Such information has led us to hypothesize that 5HT receptors may play a role in mediating ocular aqueous humor dynamics and thus in modulating IOP. However, even though 5HT 1A receptors have been found in the rabbit iris-ciliary body 11 and indeed 5HT 1A agonists such as flesinoxan 12 and 5-methyl-urapidil 13 lower IOP in the rabbit, 14, 15 the latter agents are ineffective in the monkey. 16 To complicate matters further, another 5HT 1A agonist, 5-carboximidotryptamine (5-CT), actually increases IOP in the rabbit. 17 Furthermore, potent ␣-1 adrenoceptor antagonist activity associated with the 5HT 2 antagonists ketanserin 18 -20 and sarpogrelate (Takenaka H, et al. IOVS 1995;36:ARVO Abstract 3390) in human subjects confound observations of their ocular hypotensive activity. Therefore, there appear to be major species differences in the IOP-lowering activity of the various aforementioned serotonergic agents. However, since initial studies have revealed that certain agonists of the 5HT 2 receptor class lower IOP in conscious ocular hypertensive cynomolgus monkeys, 16 we decided to examine the relative abundance of the mRNAs for various 5HT receptor subtypes in human trabecular meshwork (h-TM) cells isolated from several human donor eyes. Then, we studied the functional coupling of the predominant 5HT receptor subtypes present on TM cells using phosphoinositide (PI) turnover and intracellular Ca 2ϩ ([Ca 2ϩ ] i ) mobilization assays involving a broad range of serotonergic agonists and antagonists. Additional biochemical and pharmacological assays were used to extend the data obtained from the aforementioned assays. Furthermore, a variety of serotonergic agonists and antagonists were tested for their ability to lower IOP in the conscious ocular hypertensive cynomolgus monkey and in an effort to correlate the in vitro findings with the in vivo effects of these compounds.
MATERIALS AND METHODS

Human Donor Details
h-TM cells were isolated from TM tissue dissected from human donor eyes within 24 to 36 hours after death. Details about the human donors whose TM cells responded to 5HT 2 agonists were as follows: age, 48 days to 95 years; gender, 14 males and 10 females; number of 5HT 2 agonist-responders, 20 of 24; and responder donors with a history of glaucoma, 6. The donor tissue was obtained and managed in accordance with the guidelines in the Declaration of Helsinki. using oligonucleotide primers based on the genomic sequences of the human 5HT receptors obtained from GenBank and as recently described (http://www.ncbi.nlm.nih.gov/Genbank; provided in the public domain by the National Center for Biotechnology Information, Bethesda, MD). 21 PCR amplification products were separated by electrophoresis and visualized by UV light. Positive control tissue samples (whole human brain) were run along with the h-TM cell samples. Endonucleotide digestion was used to confirm the PCR product identities.
[ 125 I]-DOI and GTP-␥-S 35 Binding to Cloned Human 5-HT 2 
Receptors
Binding of the agonist radioligand [
125 I]-DOI to cell membranes of Chinese hamster ovary (CHO) cells transfected with full-length clones of human 5HT 2A , 5HT 2B , and 5HT 2C receptors was determined using standard radioligand binding procedures. 16 These studies were conducted at Cerep Inc. (Poitiers, France).
To determine the functional activity of certain compounds of interest at the cloned human 5HT 2A and 5HT 2C receptors, a GTP-␥-S 35 binding assay was conducted at Cerep Inc., as previously described.
22
PI Turnover Assays
The relative agonist activity of serotonergic compounds at the 5-HT 2 receptor was determined in vitro using the ability of the compounds to stimulate the production of [ 3 H]inositol phosphates in h-TM cells. 23, 24 In brief, [ 3 H] myo-inositol-labeled h-TM cells were challenged with the test compounds for 1 hour at 37°C followed by assay termination using ice-cold 0.1 M formic acid. The total [ 3 H]inositol phosphates produced were determined by anion exchange chromatography. 23, 24 Concentration-response data were analyzed by a four-parameter nonlinear (sigmoidal) curve fit function (Origin Scientific Graphics software; Microcal Software, Northampton, MA; or Excel-fit; IDBS, Surrey, UK) to determine agonist potency (EC 50 ) and efficacy (E max ). 23, 24 Serotonin (5-HT) was used as a positive control (standard) agonist compound, and the efficacy of test compounds was compared with that of 5-HT (set at 100%).
[Ca 2؉ ] i Mobilization Assays
The receptor-mediated mobilization of intracellular calcium ([Ca 2ϩ ] i ) was studied with a fluorescence imaging plate reader (FLIPR), as previously described. 25, 26 The h-TM cells from numerous donors were grown in a normal medium of DMEM-10% FBS and 10 g/mL gentamicin. Confluent cell monolayers were trypsinized, centrifuged, and resuspended in normal medium. Cells were seeded in a 50-L volume at a density of ϳ20,000 cells per well in a black walled, 96-well tissue culture plate and grown for 2 days. On the day of the experiment, a vial of FLIPR calcium assay kit dye was resuspended in 50 mL of a FLIPR buffer consisting of Hanks' balanced salt solution (HBSS), 20 mM HEPES, and 2.5 mM probenecid (pH 7.4). Cells were loaded with the calcium-sensitive dye by addition of an equal volume (50 L) to each well of the 96-well plate and incubated with dye for 1 hour at 23°C. Compounds were diluted 1:50 in 20% dimethyl sulfoxide (DMSO)-20% ethanol. For dose-response experiments, compounds were diluted 1:50 in FLIPR buffer and serially diluted 1:10 to give a 5-or 8-point concentration-response curve. Other details have been described. 25, 26 Responses were measured as peak fluorescence intensity minus basal and, where appropriate, were expressed as a percentage of a maximum 5-HT-induced response. Data were analyzed as described for the PI turnover experiments.
Aequorin-Based Intracellular [Ca 2؉ ] i Mobilization Assay
Aequorin-based intracellular [Ca 2ϩ ] i mobilization assays involving CHO-K1 cells transfected with the full-length human 5HT 2A-C receptors were used to determine agonist potency of various agents. These studies were performed at Euroscreen (Gosselies, Belgium). In brief, functional response at the 5-HT 2 receptor subtypes was determined using CHO-K1 cells stably expressing mitochondrially targeted bioluminescent aequorin, G ␣16 , and one of either cloned human 5-HT 2A , 5-HT 2B , or 5-HT 2C serotonin receptors. Before testing, cells were loaded in suspension with coelenterazine for 4 to 16 hours and directly injected onto different concentrations of the test compound. Light emitted from the cells was measured 20 to 30 seconds after receptor activation. A luminometer (FDSS-6000; Hamamatsu, Osaka, Japan) was used to record luminescence in response to the test compound. The mean response signal at each of 8 to 11 different concentrations was integrated to provide an estimation of receptor activation, expressed as the EC 50 . The E max of the response at the 5-HT 2A and 5-HT 2B receptors was expressed relative to the response of ␣-methyl-5-HT under the same assay conditions, whereas the efficacy at 5-HT 2C was expressed relative to the response of 5-HT.
IOP Measurements
IOP was determined in conscious ocular hypertensive cynomolgus monkeys using a pneumatonometer (Alcon Ltd., Fort Worth, TX) after light corneal anesthesia with 0.1% proparacaine. 16, 27 Test compounds were formulated in phosphate-buffered saline vehicle containing 0.01% benzalkonium chloride, 0.01% disodium EDTA, 0.05% polysorbate 80, and 0.5% hydroxypropylmethylcellulose and adjusted to pH 7.4. Eyes were rinsed with saline after each measurement. After a baseline IOP measurement, test compound in one 30-L aliquot was instilled in the test eyes of eight to nine animals per group per study. Vehicle was instilled in the test eyes of five to six additional animals. Subsequent IOP measurements were taken at 1, 3, and 6 hours. A compound was considered efficacious in hypertensive eyes if there was a decrease from baseline IOP of at least 20% after topical administration of test agents. Maximum IOP reduction was calculated as a percentage of the difference from baseline.
Animal Management
All nonhuman primates were cynomolgus monkeys (Macaca fascicularis) received from the Charles River Primate Corp. (Wilmington, MA) or Hazelton Research Products, Inc. (Denver, PA). Animals were male and female adults that were part of a permanent colony dedicated to glaucoma research. Each animal was permanently identified with a unique number tattooed on the abdomen. Previously, hypertension had been induced in the right eyes of all animals by laser trabeculoplasty. All left eyes were normal and normotensive. Animals had been trained to sit in restraint chairs and conditioned to accept the pressure measurements without chemical restraint. The animals were housed singly in stainless steel squeeze-back suspended wire-bottomed cages, had access to tap water ad libitum, and were fed a standard diet (Certified Laboratory Primate Diet No. 5048; PMI, Brentwood, MO) twice daily and supplemental fresh fruit. No contaminants were known to be present in the diet or drinking water that would interfere with or affect the ocular studies. Lighting in the animal room was controlled to give 14 hours of light and 10 hours of dark each day. Room temperature was maintained at an average 25°C. Humidity was maintained at Ն35%. Animals were transferred from holding cages to restraint chairs using the pole-and-collar method, a procedure to which all animals had been trained. Animals were in the chairs for no longer than 8 hours at a time. Animal studies were conducted in accordance with the resolutions for the use of laboratory animals as adopted by the National Institutes of Health and the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. 
RESULTS
RT-PCR studies revealed that h-TM cells from multiple donor eyes expressed robust mRNA signals for 5HT 2A and 5HT 2B receptors but relatively weak signals for 5HT 2C , 5HT 5 , and 5HT 7 receptors and no apparent mRNA signals for 5HT 3 , 5HT 4 , and 5HT 6 receptors ( Fig. 1 Table 2 . The PI turnover responses induced by 5HT were potently antagonized by the 5HT 2A receptor antagonist M-100907 (K i ϭ 0.13 Ϯ 0.09 nM; n ϭ 5) but less potently by the 5HT 2C receptor antagonist RS-102221 (K i ϭ 43 nM; Fig. 2,  bottom) .
The agonist potencies (EC 50 ) of the compounds in [Ca 2ϩ ] i mobilizing assays in h-TM cells were (nM): 5-methoxy tryptamine, 8; (R)-DOI, 18; ␣-methyl-5HT, 22; 5HT, 40 Ϯ 7; 5-methoxy-dimethyl tryptamine, 64; and BW-723C86, 1213 (Table 3).
To define the specificity of these agonists for 5HT 2 receptor subtypes, we obtained their ligand binding affinities at cloned human 5HT 2 receptor subtypes using competition studies involving [
125 I]-DOI binding to membranes of CHO cells transfected with recombinant 5HT 2 receptor subtypes. These data are shown in Table 4 . The rank order of potency of the various agonists in the h-TM cell-based assays and in the cloned human 5HT 2A-C receptors was quite similar (Tables 3, 5). In addition, the functional agonist potency of many of the compounds were determined at the recombinant human 5HT 2A-C receptors using aequorin-based [Ca 2ϩ ] i mobilizing assays, and these data are shown in Table 5 . Typically, the potency of compounds were lower in GTP-␥-S 35 binding as a functional readout compared with the [Ca 2ϩ ] i mobilizing assays (Table 5 ). Table 6 ). Likewise, M-100907 potently antagonized the 5HT-induced PI turnover in h-TM cells (Fig. 2,  bottom) . There was good correlation between agonist and antagonist potencies and rank order of activities in the PI turnover and [Ca 2ϩ ] i mobilizing assays (r ϭ 0.81; P Ͻ 0.02; Fig. 5 ). Of note, the only positive correlation between the pharmacology of functional [Ca 2ϩ ] i mobilizing responses in the h-TM cells and that of the cloned human 5HT 2 receptors was with the 5HT 2A subtype (r ϭ 0.74, P Ͻ 0.05) but not with 5HT 2B subtype (r ϭ 0.55, P Ͻ 0.55) or 5HT 2C subtype (r ϭ 0.22, P Ͻ 0.63). Relative abundances of 5HT receptor subtype mRNA signals were obtained from h-TM cells isolated from eight different human donor eyes (ages from 6 months to 88 years). The primers used for the 5HT 1A receptor were unsuccessful; hence, no data are presented for this receptor subtype. The relative abundance of mRNAs is represented in an ascending scale of plus signs, with ϩ denoting relatively low and ϩϩϩ denoting very high relative levels of mRNA signals. Minuses signify that mRNA for the receptor was undetectable under the present conditions. The data for h-ciliary body are from Ref. 21 5HT 2 agonists like (R)-DOI, 5HT, ␣-methyl-5HT, but not 5HT 2 antagonists, lowered IOP in conscious ocular hypertensive cynomolgus monkeys (Table 7) . Ligands for other 5HT receptor families including agonists and antagonists for 5HT 1A , 5HT 1D , 5HT 3 , 5HT 4 , 5HT 6 , and 5HT 7 receptors and a 5HT uptake inhibitor were essentially devoid of any ocular hypotensive activity in the lasered monkey eyes (Table 7) .
DISCUSSION
The present studies have demonstrated the presence of the mRNAs for 5HT 2A and 5HT 2B receptors, with a lower signal for 5HT 2C receptor mRNA, in h-TM cells isolated from several human donors' eyes using RT-PCR techniques. Of note, the ] i mobilization over seconds on exposure to the various concentrations of these agonists. The peak response amplitudes from such assays were used to construct the concentration-response curves in Figure 4 (top). The fact that the mRNAs for 5HT 2 receptors are most probably translated into their respective receptor proteins in the h-TM cells was confirmed by the detection of functional responses to numerous serotonergic agonists known to be activators of 5HT 2 receptors including 5HT, ␣-methyl-5HT, and (R)-DOI ( Figs. 2-4 ; Tables 2, 3 ). 5HT 2 agonists stimulated PI turnover and/or mobilized [Ca 2ϩ ] i in 20 of 24 TM cell strains isolated from up to 24 different human donor eyes, thus indicating a high degree of responsiveness to serotonergic agonists in the current population of donor cells studied. 5HT 2A receptor agonists (e.g., ␣-methyl-5HT, (R)-DOI) or nonselective 5HT 2 agonists (e.g., 5-methoxy tryptamine) were the most potent compounds when tested in the PI turnover (Table 2) and [Ca 2ϩ ] i mobilizing (Table 3 ) assays in h-TM cells, whereas agonists claimed to be relatively selective for 5HT 2B receptors (e.g., BW-723C86) 28 and 5HT 2C receptors (MK-212; mCPP) 29 -32 were weak agonists, exhibiting much lower intrinsic activities than other agonists tested (Tables 2, 3 ). These observations strongly suggest that the predominant receptor being expressed and functionally active in the h-TM cells was the 5HT 2A receptor subtype. We tried first to correlate these observations with the relative receptor binding affinities of various compounds at the recombinant human 5HT 2A-C receptors but without success. However, a better comparison was found between functional agonist potencies in h-TM and recombinant human 5HT 2 receptor subtypes. The functional potencies of various 5HT 2 agonists were somewhat different when determined in the aequorin-based [Ca 2ϩ ] i mobilizing assays using cloned human 5HT 2A-C receptors (Table 5) relative to the potency values obtained from h-TM cells (Tables 3, 6 ). However, in general the relative receptor selectivity indicated by the cloned receptor data helped to confirm the conclusion that the 5HT 2A receptor was being predominantly expressed in the h-TM cells. This conclusion was further supported by antagonist data (Figs. 2, 4 , bottom; Table 6 ). Thus, the 5HT 2A -selective antagonist, M-100907, was the most potent antagonist in the TM cell PI turnover assays and in the [Ca 2ϩ ] i mobilizing assays, Data are the mean Ϯ SEM from 3 to 9 experiments in cells isolated from several different human donor eyes. EC 50 and E max have been rounded off to the nearest whole number when possible, to permit easier comparisons among the compounds. 
Data are the mean Ϯ SEM from 3 or more experiments involving [ 125 I]-DOI binding to membranes of CHO cells expressing specific recombinant human 5HT 2 receptor subtypes. Also see Ref. 16 . Note that the K i is inversely related to the relative affinity of the compound. being more than 1000 times more potent that antagonists for the 5HT 2B and 5HT 2C receptors. 28 -32 There was a good correlation (r ϭ 0.81; P Ͻ 0.02) between the relative functional potencies of agonists and antagonists mediating PI hydrolysis and mobilizing [Ca 2ϩ ] i in h-TM cells (Fig. 5) . Likewise, the pharmacology of the [Ca 2ϩ ] i mobilizing and antagonism of these responses in the h-TM cells correlated well with that of the cloned human 5HT 2A receptor (r ϭ 0.74, P Ͻ 0.05), but not with cloned human 5HT 2B (r ϭ 0.27) or 5HT 2C (r ϭ 0.22) receptors. This further confirmed the nature of the predominant functional receptor in h-TM cells. Of note, a 5HT 2 receptor also appears to be involved in promoting PI hydrolysis in bovine ciliary epithelium as defined by the pharmacological sensitivity of this system. 33 Similarly, 5HT 2 receptors appear to mediate the contraction of bovine ciliary muscle 34 ; hence, the 5HT 2 receptor system is present in the target cells and tissues involved in aqueous humor dynamics in different species. Functional receptors of the 5HT 3 and 5HT 7 receptor family have previously been described in human and bovine iris-ciliary body, 35, 36 whereas 5HT 1A receptor-binding sites have been detected in rabbit iris-ciliary body tissue homogenates. 11 Therefore, a variety of 5HT receptor families are represented in the ocular tissues of the anterior chamber and are presumably involved in diverse physiological effects in the eye, perhaps including aqueous humor dynamics.
As a corollary to the in vitro results obtained from isolated human TM cells we wanted to study the effects of various serotonergic agents on their ability to modulate IOP in vivo. Because such studies are difficult to conduct in human subjects, we decided that nonhuman primates would suffice, considering that the cynomolgus monkey model has successfully predicted IOP-lowering efficacy of numerous classes of compounds in human subjects. [3] [4] [5] 27 Accordingly, various 5HT agents were tested for their effects on IOP in conscious ocular hypertensive cynomolgus monkey eyes. It was gratifying to observe that 5HT 2 agonists, either 5HT 2A -selective or nonselective, were the most efficacious IOPlowering compounds found among numerous serotonergic agents tested (Table 7) . Thus, the most potent and efficacious agent was (R)-DOI followed by ␣-methyl-5HT and 5-methoxy-N,N-dimethyl-tryptamine, all with equal or greater efficacy than positive control ocular hypotensive agents, brimonidine, levobetaxolol, pilocarpine, and travoprost (Table 7) . Although one 5HT 2C agonist (mCPP) lowered IOP (22.8%, P Ͻ 0.05), another 5HT 2C agonist, MK-212, was essentially inactive (Table 6) . A 5HT 2B -selective agonist, BW-723C86 (18.0%, P Ͼ 0.05), also lacked ocular hypotensive activity, further emphasizing that 5HT 2A receptors predominantly are involved in lowering IOP in the ocular hypertensive cynomolgus monkey eyes. Whereas 5HT 1A agonists such as 8-OH-DPAT, DP-5-CT, and flesinoxan exhibited ocular hypotensive activities in rabbit eyes, 11, 12, 14, 15, 17 these compounds, and nonselective 5HT receptor antagonists such as metergoline (16.9%, P Ͼ 0.05) and methiothepin (18.3% P Ͻ 0.05) had noticeably minimal effects on IOP in cynomolgus monkey eyes (Table 7) . Thus, there are significant species differences in the ocular hypotensive activity of serotonergic compounds, and it is imperative that IOP effects of compounds be determined in humans or at least nonhuman primates to permit some degree of extrapolation to the human situation. It is also clear from data in Table 7 that agonists and/or antagonists of non-5HT 2 receptor families, such as 5HT 3 , 5HT 4 , 5HT 6 , and 5HT 7 , were devoid of ocular hypotensive activity, thus further emphasizing the involvement of the 5HT 2 receptor in the IOP-lowering activity of certain serotonergic agonist compounds.
Historically, a few reports have suggested that antagonists of 5HT 2 receptors, such as ketanserin and its analogues 18 -20,37-39 and sarpogrelate (Takenaka H, et al. IOVS 1995;36:ARVO Abstract 3390) are ocular hypotensive agents in animals and humans. However, it is clear now that it is the ␣-1 adrenergic antagonist activity that is responsible for the IOP-lowering actions of these compounds 13, 18, 40 and not their 5HT 2 antagonist activity. Of note, however, numerous 5HT 2A-C receptor antagonists, including ketanserin, ritanserin, M-100907, 41 SB-206553, RS-102221, SB-242084, 42 even up to 300 g topical ocular doses, failed to lower IOP in the conscious ocular hypertensive cynomolgus monkey eyes (Table 7) . Thus, those earlier observations require careful scrutiny. Whereas it is not possible to ascribe a precise mechanism of action of 5HT 2A agonists for lowering IOP in monkey eyes, one report 43 suggested that an increase in uveoscleral outflow was induced by (R)-DOI in normotensive cynomolgus monkey eyes. Whether uveoscleral outflow, coupled with conventional trabecular meshwork outflow, is activated by 5HT 2A agonists in ocular hypertensive monkey eyes remains to be determined. It is worth noting, however, that even though uveoscleral outflow is predominantly stimulated by FP-class prostaglandins, 2-5 recent observations of FP-receptor-mediated relaxation of endothelin-induced TM contraction 44 supports a conventional outflow component for FP-agonist-mediated IOP reduction. 44 Consequently, we can speculate that a similar conventional outflow component of 5HT 2 -agonist-mediated ocular hypotension may prevail, because we have demonstrated the presence of 5HT 2 receptors in h-TM cells (this study) akin to our previously published work on FP-prostaglandin receptors in h-TM cells. 45 However, much more work is needed to demonstrate the precise mechanism(s) by which 5HT 2 agonists lower IOP in ocular hypertensive monkeys.
In summary, our in vitro studies demonstrated the presence of mRNAs for 5HT 2A and 5HT 2B receptors in h-TM cells, with a functional expression predominantly of the 5HT 2A receptor signal transduction mechanisms, including PI hydrolysis followed by [Ca 2ϩ ] i mobilization in these cells isolated from several human donor eye TM tissues. These conclusions were derived from extensive pharmacological studies involving numerous agonists and antagonists. As a corollary to these studies, we were able to demonstrate that indeed it is the 5HT 2 receptor, again predominantly the 5HT 2A subtype, which is involved in lowering IOP in conscious ocular hypertensive cynomolgus monkey eyes. Therefore, 5HT 2A receptor agonists represent a novel class of ocular hypotensive agents worthy of further pursuit for glaucoma therapy. Data are the mean Ϯ SEM from 3 independent experiments in cells obtained from different donors. For comparison, antagonist potencies for some of these compounds in the PI turnover assays were: M-100907, K i ϭ 0.13 Ϯ 0.09 nM (n ϭ 5); RS-102221, K i ϭ 43 nM). 
